Skip to content

the Anatomical Reduction and Functional Recovery Effects of Two Transvaginal Apical Slings on Pelvic Organ Prolapse

A Randomized Controlled Study on the Anatomical Reduction and Functional Recovery Effects of Two Transvaginal Apical Slings on Pelvic Organ Prolapse

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05189665
Enrollment
124
Registered
2022-01-12
Start date
2021-10-01
Completion date
2023-04-30
Last updated
2022-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Organ Prolapse

Keywords

Extraperitoneal high uterosacral ligament suspension

Brief summary

The study is a prospective study at a single institution. Investigators create strict inclusion and exclusion criteria, selecting 124 patients with POP(≥II degree and have symptoms that need operation) . 62 patients in the intervention group accept extraperitoneal high uterosacral ligament suspension. The other 62 patients in the other group accept sacrospinous ligament suspension.

Detailed description

Investigators evaluate all women's operation method, operation time, bleed volume, overactive bladder questionnaire, PFDI-20,ICIQ-SF, I-QoL, PISQ-12, PFIQ-7, UDI-6, pre- and post-operation (at 1 month, 3 months, 6months and 1 year).

Interventions

PROCEDUREExtraperitoneal high sacral ligament suspension surgery

The extraperitoneal high sacral ligament suspension surgery is to shorten the bilateral uterosacral ligaments .

The sacrospinous ligament fixation surgery is to open the front and back peritoneum through the vagina and shorten the bilateral uterosacral ligaments.

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Age ≥30 years old; pelvic organ prolapse, with or without abnormal urination or defecation or sexual disturbance, which affects the quality of life Pelvic organ prolapse quantitation (POP-Q) is greater than or equal to Those who are in stage II and have symptoms and require surgery The patient agrees to conduct the study and can be followed up on time.

Exclusion criteria

Those who cannot tolerate surgery and anesthesia Those who need to remove the uterus Those who have removed the uterus Those who cannot be followed up on time.

Design outcomes

Primary

MeasureTime frameDescription
changes in POP-Q score at different time nodespre-operation and post-operation(at 1month, 3 month, 6 month and a year)Gynecological examination

Secondary

MeasureTime frameDescription
Postoperative urinary incontinence assessmentpost-operation(at 1month, 3 month, 6 month and a year)One hour pad test
OABss score at different time nodespost-operation(at 1month, 3 month, 6 month and a year)Questionnaires lower urinary tract symptoms
PFDI-20 score at different time nodespost-operation(at 1month, 3 month, 6 month and a year)Questionnaires on pelvic floor function and lower urinary tract symptoms and quality of life
UDI-6 scores at different time nodes UDI-6pre-operation and post-operation(at 1month, 3 month, 6 month and a year)Questionnaires on lower urinary tract symptoms and quality of life
I-QoL score at different time nodespost-operation(at 1month, 3 month, 6 month and a year)Questionnaires on lower urinary tract symptoms and quality of life
PISQ-12 score at different time nodespost-operation(at 1month, 3 month, 6 month and a year)Questionnaires on pelvic floor function and lower urinary tract symptoms and sexual quality of life
PFIQ-7 score at different time nodespost-operation(at 1month, 3 month, 6 month and a year)Questionnaires on pelvic floor function and quality of life
ICIQ-SF score at different time nodespost-operation(at 1month, 3 month, 6 month and a year)Questionnaires on lower urinary tract symptoms

Countries

China

Contacts

Primary Contactxiuli sun, professor
sunxiuli03351@126.com010-88324354

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026